NICE accepts PAD treatment

Intermittent claudication can significantly impair mobility in people with PAD. | SCIENCE PHOTO LIBRARY
Intermittent claudication can significantly impair mobility in people with PAD. | SCIENCE PHOTO LIBRARY

Naftidrofuryl oxalate can now be prescribed on the NHS for the treatment of intermittent claudication caused by peripheral arterial disease (PAD). It may be used in patients for whom vasodilator therapy is considered appropriate.

Although naftidrofuryl oxalate does not halt the progression of PAD, it is believed to be the most clinically and cost effective treatment option in terms of improving maximum walking distance.

NICE rejected the other vasodilators cilostazol, pentoxifylline and inositol nicotinate for intermittent claudication in PAD on the grounds that they are not as clinically effective compared with placebo as naftidrofuryl oxalate.

View naftidrofuryl drug record

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more